NZ512788A - Transdermal patch for delivering volatile liquid drugs - Google Patents
Transdermal patch for delivering volatile liquid drugsInfo
- Publication number
- NZ512788A NZ512788A NZ512788A NZ51278899A NZ512788A NZ 512788 A NZ512788 A NZ 512788A NZ 512788 A NZ512788 A NZ 512788A NZ 51278899 A NZ51278899 A NZ 51278899A NZ 512788 A NZ512788 A NZ 512788A
- Authority
- NZ
- New Zealand
- Prior art keywords
- drug
- layer
- nicotine
- patch
- mecamylamine
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 239000007788 liquid Substances 0.000 title claims abstract description 18
- 239000010410 layer Substances 0.000 claims abstract description 97
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 67
- 229960002715 nicotine Drugs 0.000 claims abstract description 67
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 67
- 239000013464 silicone adhesive Substances 0.000 claims abstract description 38
- 239000003522 acrylic cement Substances 0.000 claims abstract description 18
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims description 56
- 229960002525 mecamylamine Drugs 0.000 claims description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 51
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 28
- 239000000853 adhesive Substances 0.000 claims description 22
- 230000001070 adhesive effect Effects 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 18
- 229960003946 selegiline Drugs 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000010030 laminating Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 abstract description 24
- 206010057852 Nicotine dependence Diseases 0.000 abstract description 8
- 208000025569 Tobacco Use disease Diseases 0.000 abstract description 8
- 230000004907 flux Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 239000012790 adhesive layer Substances 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 10
- 229920001296 polysiloxane Polymers 0.000 description 10
- 229920000728 polyester Polymers 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 230000000391 smoking effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 6
- 238000003475 lamination Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000005266 casting Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- -1 polysiloxane Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11128598P | 1998-12-07 | 1998-12-07 | |
| PCT/US1999/028697 WO2000033812A2 (en) | 1998-12-07 | 1999-12-07 | Transdermal patch for delivering volatile liquid drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ512788A true NZ512788A (en) | 2003-07-25 |
Family
ID=22337613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ512788A NZ512788A (en) | 1998-12-07 | 1999-12-07 | Transdermal patch for delivering volatile liquid drugs |
| NZ52587899A NZ525878A (en) | 1998-12-07 | 1999-12-07 | A method of treating nicotine dependance with mecamylamine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ52587899A NZ525878A (en) | 1998-12-07 | 1999-12-07 | A method of treating nicotine dependance with mecamylamine |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1137406B2 (https=) |
| JP (1) | JP2002531488A (https=) |
| KR (1) | KR100885235B1 (https=) |
| AT (1) | ATE264098T1 (https=) |
| AU (1) | AU778992B2 (https=) |
| CA (1) | CA2380391A1 (https=) |
| DE (1) | DE69916492T3 (https=) |
| NZ (2) | NZ512788A (https=) |
| WO (1) | WO2000033812A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| ATE288256T1 (de) | 1999-01-14 | 2005-02-15 | Noven Pharma | Dermale zusammensetzungen |
| US20030170195A1 (en) | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
| ES2310201T3 (es) | 2001-02-13 | 2009-01-01 | Government Of The United States Of America, As Represented By The Secretary Of The Army | Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros. |
| DE10110391A1 (de) | 2001-03-03 | 2002-09-26 | Lohmann Therapie Syst Lts | Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff |
| CN1516595A (zh) * | 2001-03-19 | 2004-07-28 | Iomai公司 | 用于经皮免疫的贴剂 |
| US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
| US20040086551A1 (en) | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| ES2294480T3 (es) * | 2003-03-14 | 2008-04-01 | Agi Therapeutics Research Limited | Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina. |
| US20070224284A1 (en) | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| EP1682102A2 (en) | 2003-09-10 | 2006-07-26 | Noven Pharmaceuticals, Inc. | Multi-layer transdermal drug delivery device |
| MEP23508A (en) | 2003-10-28 | 2010-06-10 | Noven Pharma | Compositions and methods for comtrolling drug loss and delivery in transdermal drug delivery systems |
| ITMI20041697A1 (it) * | 2004-09-03 | 2004-12-03 | Bouty S P A | Sistema terapeutico a rilascio controllato per uso topico in forma di cerotto multistrato |
| US8343538B2 (en) | 2004-10-08 | 2013-01-01 | Noven Pharmaceuticals, Inc. | Compositions and methods for controlling the flux of a drug from a transdermal drug delivery systems |
| WO2006041911A2 (en) | 2004-10-08 | 2006-04-20 | Noven Pharmaceuticals, Inc. | Device transdermal administration of drugs including acrylic polymers |
| IL177071A0 (en) | 2005-08-01 | 2006-12-10 | Nitto Denko Corp | Method of preparing a nicotine transdermal preparation |
| EP1774964B1 (en) | 2005-10-13 | 2014-08-06 | Nitto Denko Corporation | Nicotine transdermal preparation and production method thereof |
| DE102006054733A1 (de) | 2006-11-21 | 2008-05-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit |
| CA2733265A1 (en) * | 2008-09-30 | 2010-04-08 | Teikoku Pharma Usa, Inc. | Transdermal extended-delivery donepezil compositions and methods for using the same |
| EP2298277A1 (en) * | 2009-09-09 | 2011-03-23 | Labtec GmbH | Transdermal patch formulation |
| MX2012012069A (es) * | 2010-04-30 | 2012-11-22 | Teikoku Pharma Usa Inc | Composiciones transdermicas de propinilaminoindan. |
| KR101853082B1 (ko) | 2011-03-24 | 2018-04-27 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 활성제층 및 활성제 변환층을 포함하는 경피 조성물 |
| JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
| JP6050896B2 (ja) | 2012-11-02 | 2016-12-21 | テイコク ファーマ ユーエスエー インコーポレーテッド | プロピニルアミノインダン経皮組成物 |
| DE102013013397A1 (de) | 2013-08-13 | 2015-03-12 | Epinamics Gmbh | Aerosolspender für transdermal wirkende pharmazeutische Zusammensetzungen |
| DE102013020633A1 (de) | 2013-12-16 | 2015-06-18 | Epinamics Gmbh | Dermale und/oder transdermale pharmazeutische Zusammensetzung enthaltend eine terpenoide Verbindung |
| DE102020112143B4 (de) | 2020-05-05 | 2022-03-17 | Lts Lohmann Therapie-Systeme Ag | Nicotin - Corona |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4717568A (en) * | 1985-08-09 | 1988-01-05 | Alza Corporation | Laminar arrangement for increasing delivery of beneficial agent from dispenser |
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| DE3629304A1 (de) † | 1986-08-28 | 1988-03-24 | Lohmann Gmbh & Co Kg | Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung |
| CH674618A5 (https=) * | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag | |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| GB8807504D0 (en) † | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| DE3908432A1 (de) * | 1989-03-14 | 1990-09-27 | Lohmann Therapie Syst Lts | Pflaster als therapeutisches system zur verabreichung von wirkstoffen an die haut mit einer abgestuften wirkstoffabgabe, verfahren zu seiner herstellung sowie verwendung |
| DE3910543A1 (de) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung |
| DE69422925T2 (de) † | 1993-07-09 | 2000-08-17 | Cygnus, Inc. | Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten |
| DE4332094C2 (de) † | 1993-09-22 | 1995-09-07 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung |
| ATE246909T1 (de) * | 1994-03-07 | 2003-08-15 | Theratech Inc | Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung |
| IL122484A0 (en) * | 1995-06-07 | 1998-06-15 | Noven Pharma | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
| JPH09301853A (ja) * | 1996-05-14 | 1997-11-25 | Nitto Denko Corp | 貼付剤および貼付製剤 |
-
1999
- 1999-12-07 AU AU25877/00A patent/AU778992B2/en not_active Ceased
- 1999-12-07 AT AT99968461T patent/ATE264098T1/de not_active IP Right Cessation
- 1999-12-07 JP JP2000586306A patent/JP2002531488A/ja active Pending
- 1999-12-07 NZ NZ512788A patent/NZ512788A/en not_active IP Right Cessation
- 1999-12-07 DE DE69916492T patent/DE69916492T3/de not_active Expired - Lifetime
- 1999-12-07 EP EP99968461A patent/EP1137406B2/en not_active Expired - Lifetime
- 1999-12-07 CA CA002380391A patent/CA2380391A1/en not_active Abandoned
- 1999-12-07 NZ NZ52587899A patent/NZ525878A/xx not_active IP Right Cessation
- 1999-12-07 WO PCT/US1999/028697 patent/WO2000033812A2/en not_active Ceased
- 1999-12-07 KR KR1020017007132A patent/KR100885235B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2380391A1 (en) | 2000-06-15 |
| KR100885235B1 (ko) | 2009-02-24 |
| DE69916492D1 (de) | 2004-05-19 |
| AU2587700A (en) | 2000-06-26 |
| EP1137406B1 (en) | 2004-04-14 |
| WO2000033812A2 (en) | 2000-06-15 |
| KR20010101147A (ko) | 2001-11-14 |
| NZ525878A (en) | 2004-12-24 |
| DE69916492T2 (de) | 2005-05-12 |
| EP1137406A2 (en) | 2001-10-04 |
| WO2000033812A3 (en) | 2000-11-23 |
| JP2002531488A (ja) | 2002-09-24 |
| EP1137406B2 (en) | 2008-01-23 |
| DE69916492T3 (de) | 2008-08-14 |
| ATE264098T1 (de) | 2004-04-15 |
| AU778992B2 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6974588B1 (en) | Transdermal patch for delivering volatile liquid drugs | |
| EP1137406B1 (en) | Transdermal patch for delivering volatile liquid drugs | |
| WO2000033812A9 (en) | Transdermal patch for delivering volatile liquid drugs | |
| EP0708627B1 (en) | Method and device for providing nicotine replacement therapy transdermally/transbuccally | |
| AU695170B2 (en) | Transdermal delivery system with adhesive overlay and peel seal disc | |
| AU586770B2 (en) | Transdermal verapamil delivery device | |
| US5091186A (en) | Biphasic transdermal drug delivery device | |
| US9320742B2 (en) | Transdermal testosterone device and delivery | |
| RU2526186C2 (ru) | Средство и способ трансдермальной доставки эстрогена | |
| US8784874B2 (en) | Multi-layer transdermal drug delivery device | |
| JP2002531488A5 (https=) | ||
| EP1585470A2 (en) | Transdermal delivery of fentanyl | |
| WO2016109483A1 (en) | Transdermal drug delivery systems for agomelatine | |
| JP7354242B2 (ja) | イブプロフェンまたはその構造類似体を含む多層経皮薬物送達システム | |
| EP1449527A2 (en) | Transdermal patch for administering a volatile liquid drug | |
| CA2279994A1 (en) | Extendible transdermal therapeutic system | |
| JP7625623B2 (ja) | レボノルゲストレルおよびエチニルエストラジオールのための経皮的薬物送達システム | |
| US20180360769A1 (en) | Systems and methods for transdermal drug delivery | |
| HK1075816B (en) | Transdermal delivery of fentanyl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AVOD | Application void | ||
| CORR | Corrigendum |
Free format text: ADVERTISED AS VOID IN JOURNAL 1485 IN ERROR THE CURRENT STATUS IS EXAMINATION |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |